Roche cancer immunotherapy receives new EU approval
The subcutaneous injection of the novel cancer immunotherapy Tecentriq® (atezolizumab)…
16 January 2024 | By
The subcutaneous injection of the novel cancer immunotherapy Tecentriq® (atezolizumab) could provide a quicker alternative to intravenous infusion, research shows.